NO20071889L - Middel for profylakse eller behandling av stoffskiftesyndrom. - Google Patents

Middel for profylakse eller behandling av stoffskiftesyndrom.

Info

Publication number
NO20071889L
NO20071889L NO20071889A NO20071889A NO20071889L NO 20071889 L NO20071889 L NO 20071889L NO 20071889 A NO20071889 A NO 20071889A NO 20071889 A NO20071889 A NO 20071889A NO 20071889 L NO20071889 L NO 20071889L
Authority
NO
Norway
Prior art keywords
prophylaxis
treatment
metabolic syndrome
remedy
oxadiazol3
Prior art date
Application number
NO20071889A
Other languages
English (en)
Norwegian (no)
Inventor
Nobuhiro Nishigaki
Original Assignee
Takeda Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35517142&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20071889(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co filed Critical Takeda Pharmaceutical Co
Publication of NO20071889L publication Critical patent/NO20071889L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20071889A 2004-10-07 2007-04-12 Middel for profylakse eller behandling av stoffskiftesyndrom. NO20071889L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004294889 2004-10-07
JP2005125373 2005-04-22
PCT/JP2005/018823 WO2006038722A1 (en) 2004-10-07 2005-10-06 Agent for prophylaxis or treatment of metabolic syndrome

Publications (1)

Publication Number Publication Date
NO20071889L true NO20071889L (no) 2007-06-26

Family

ID=35517142

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071889A NO20071889L (no) 2004-10-07 2007-04-12 Middel for profylakse eller behandling av stoffskiftesyndrom.

Country Status (17)

Country Link
US (1) US20070270477A1 (es)
EP (1) EP1799203A1 (es)
JP (1) JP2008515767A (es)
KR (1) KR20070073872A (es)
AR (1) AR052015A1 (es)
AU (1) AU2005290394A1 (es)
BR (1) BRPI0516246A (es)
CA (1) CA2583768A1 (es)
CR (1) CR9074A (es)
IL (1) IL182055A0 (es)
MX (1) MX2007003716A (es)
NO (1) NO20071889L (es)
PE (1) PE20060971A1 (es)
RU (1) RU2007116969A (es)
TW (1) TW200616625A (es)
UY (1) UY29155A1 (es)
WO (1) WO2006038722A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007126135A1 (en) * 2006-04-27 2007-11-08 Takeda Pharmaceutical Company Limited Pharmaceutical composition of angiotensin ii antagonists with pioglitazone hcl
JP2008195625A (ja) * 2007-02-08 2008-08-28 Pharma Frontier Kk Ｇ蛋白質共役型レセプター抑制剤および医薬
CA2782224A1 (en) * 2009-11-30 2011-06-03 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Azilsartan organic amine salts, preparation method and use thereof
US20130217778A1 (en) * 2010-07-21 2013-08-22 Herman H. Vandenburgh Methods and compositions for the improvement of skeletal muscle function in a mammal
EP2666773B1 (en) 2011-01-20 2017-07-26 Jiangsu Hansoh Pharmaceutical Co., Ltd. Organic amine salts of azilsartan, preparation method and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102183A (en) * 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
PT914158E (pt) * 1996-04-05 2002-11-29 Takeda Chemical Industries Ltd Combinacao farmaceutica que incorpora um composto que possui actividade antagonista da angiotensina ii e um composto que aumenta a sensibilidade a insulina
PL342684A1 (en) * 1998-03-04 2001-07-02 Takeda Chemical Industries Ltd Preperation featured by reterded release of aii antagonist, production and application of such preparation
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
CA2420055C (en) * 2000-08-25 2010-06-01 Takeda Chemical Industries, Ltd. Fibrinogen-lowering agent
EP1452176A4 (en) * 2001-12-03 2009-01-21 Takeda Pharmaceutical MEANS FOR IMPROVING INSULIN RESISTANCE
JP4484427B2 (ja) * 2001-12-03 2010-06-16 武田薬品工業株式会社 インスリン抵抗性改善剤
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
AU2003256419A1 (en) * 2002-08-21 2004-03-11 Merck & Co., Inc. Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist
US7582662B2 (en) * 2002-12-27 2009-09-01 Takeda Pharmaceutical Company Limited Body weight gain inhibitor

Also Published As

Publication number Publication date
US20070270477A1 (en) 2007-11-22
MX2007003716A (es) 2007-04-23
CR9074A (es) 2007-08-28
BRPI0516246A (pt) 2008-08-26
UY29155A1 (es) 2006-02-24
KR20070073872A (ko) 2007-07-10
WO2006038722A1 (en) 2006-04-13
CA2583768A1 (en) 2006-04-13
JP2008515767A (ja) 2008-05-15
AR052015A1 (es) 2007-02-28
TW200616625A (en) 2006-06-01
AU2005290394A1 (en) 2006-04-13
IL182055A0 (en) 2007-07-24
PE20060971A1 (es) 2006-11-15
RU2007116969A (ru) 2008-11-20
EP1799203A1 (en) 2007-06-27

Similar Documents

Publication Publication Date Title
AR052052A1 (es) Terapia de combinacion
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
WO2008040534A3 (en) Non-mucoadhesive film dosage forms
WO2005105088A3 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
EA201100621A1 (ru) Лечение диабета у пациентов, у которых наблюдается недостаточный гликемический контроль несмотря на лечение пероральным или непероральным противодиабетическим лекарственным средством
DK1742624T3 (da) Dopamin-agonist-kombinationsterapi med sedativer til forbedring af søvnkvalitet
FI3628319T3 (fi) Hepaattisen enkefalopatian hoito rifaksimiinilla
BRPI0615157A2 (pt) composto, composição farmacêutica, métodos para inibir a replicação viral em um paciente humano, e para tratar uma infecção viral em um paciente humano, e, uso de um composto
NO20071889L (no) Middel for profylakse eller behandling av stoffskiftesyndrom.
CY1112184T1 (el) Πυριδοξαμινη για χρηση στην αγωγη της διαβητικης nεφροπαθειας στο διαβητη τυπου ii
EA200701181A1 (ru) Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний
SG164283A1 (en) New benzimidazole derivatives
NO20091644L (no) Hurtig desintegrerende, lyofiliserte orale formuleringer av en trombinreseptorantagonist
MX2008002456A (es) Uso de ambroxol para el tratamiento de infecciones por rinovirus.
UA99489C2 (en) Crystalline chemotherapeutic agent
DOP2010000111A (es) Productos quimioterapeuticos cristalinos
NO20091659L (no) Fremgangsmater for behandling av disruptive oppforselsforstyrrelser
EA200801890A1 (ru) Средство для лечения шума в ушах
DOP2010000113A (es) Productos quimioterapeuticos cristalinos
PA8800201A1 (es) Productos quimioterapéuticos cristalinos
EA200901145A1 (ru) Применение рибофлавина в лечении гипертензии
TH82345B (th) สารสำหรับการป้องกัน หรือรักษากลุ่มอาการเมแทบอลิค
AR068792A1 (es) Composiciones agonistas de dopamina de liberacion controlada y metodo de tratamiento
AR062215A1 (es) Inhibidor de trombina activo por via oral
TH82345A (th) สารสำหรับการป้องกัน หรือรักษากลุ่มอาการเมแทบอลิค

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application